Result of AGM

3rd June 2013 Verona Pharma plc ("Verona Pharma" or the "Company") Results of AGM Verona Pharma plc (AIM: VRP), the drug development company focused on"first-in-class" medicines to treat respiratory diseases, announces that allresolutions proposed at the Annual General Meeting held today were duly passed. A presentation on Verona Pharma made by its CEO, Dr. Jan-Anders Karlsson, isavailable to view on the Company's website www.veronapharma.com. For further information please contact: Verona Pharma plc Tel: 020 7863 3300 Clive Page, Chairman Jan-Anders Karlsson, CEO WH Ireland Limited Tel: 020 7220 1666 Chris Fielding Nick Field FTI Consulting Tel: 020 7831 3113 Julia Phillips Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma is developing first-in-class drugs to treat respiratory disease,such as COPD, asthma and chronic, severe cough. The Company has three drugprogrammes, two of which are in Phase II. The lead programme, RPL554, is aninnovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with bothbronchodilator and anti-inflammatory properties. VRP700 is an innovativeproduct for suppressing chronic, severe cough in patients with underlying lungdisease. In its third programme, Verona Pharma is investigating novelanti-inflammatory molecules, called NAIPs, for a wide range of respiratory andinflammatory diseases.